Cargando…

Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China

BACKGROUND: Maintaining plasma HIV RNA suppression below the limit of quantification is the goal of antiretroviral therapy (ART). When viral loads (VL) remain in low-level viremia (LLV), or between 201 and 999 copies/mL, the clinical consequences are still not clear. We investigated the occurrence o...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Pengtao, You, Yinghui, Liao, Lingjie, Feng, Yi, Shao, Yiming, Xing, Hui, Lan, Guanghua, Li, Jianjun, Ruan, Yuhua, Li, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066819/
https://www.ncbi.nlm.nih.gov/pubmed/35509014
http://dx.doi.org/10.1186/s12879-022-07417-z
_version_ 1784699875092332544
author Liu, Pengtao
You, Yinghui
Liao, Lingjie
Feng, Yi
Shao, Yiming
Xing, Hui
Lan, Guanghua
Li, Jianjun
Ruan, Yuhua
Li, Dan
author_facet Liu, Pengtao
You, Yinghui
Liao, Lingjie
Feng, Yi
Shao, Yiming
Xing, Hui
Lan, Guanghua
Li, Jianjun
Ruan, Yuhua
Li, Dan
author_sort Liu, Pengtao
collection PubMed
description BACKGROUND: Maintaining plasma HIV RNA suppression below the limit of quantification is the goal of antiretroviral therapy (ART). When viral loads (VL) remain in low-level viremia (LLV), or between 201 and 999 copies/mL, the clinical consequences are still not clear. We investigated the occurrence of LLV with drug resistance and its effect on CD4 cell counts in a large Chinese cohort. METHODS: We analysed data of 6,530 ART-experienced patients (42.1 ± 10.9 years; 37.3% female) from the China’s national HIV drug resistance (HIVDR) surveillance database. Participants were followed up for 32.9 (IQR 16.7–50.5) months. LLV was defined as the occurrence of at least one viral load (VL) measurement of 50–200 copies/mL during ART. Outcomes were drug resistance associated mutations (DRAM) and CD4 cell counts levels. RESULTS: Among 6530 patients, 58.0% patients achieved VL less than 50 copies/mL, 27.8% with VL between 50 and 999 copies/mL (8.6% experienced LLV), and 14.2% had a VL ≥ 1000 copies/mL. Of 1818 patients with VL 50–999 copies/mL, 182 (10.0%) experienced HIVDR, the most common DRAM were M184I/V 28.6%, K103N 19.2%, and V181C/I/V 10.4% (multidrug resistance: 27.5%), and patients with HIVDR had a higher risk of CD4 cell counts < 200 cells/μL (AOR 3.8, 95% CI 2.6–5.5, p < 0.01) comparing with those without HIVDR. Of 925 patients with VL ≥ 1000 copies/mL, 495 (53.5%) acquired HIVDR, the most common DRAM were K103N 43.8%, M184I/V 43.2%, M41L 19.0%, D67N/G 16.4%, V181C/I/V 14.5%, G190A/S 13.9% and K101E 13.7% (multidrug resistance: 75.8%), and patients with HIVDR had a higher risk of CD4 cell counts < 200 cells/μL (AOR 5.8, 95% CI 4.6–7.4, p < 0.01) comparing with those without HIVDR. CONCLUSION: Persistent with VL 50–999 copies/mL on ART is associated with emerging DRAM for all drug classes, and patients in this setting were at increased risk of CD4 cell counts < 200 cells/μL, which suggest resistance monitoring and ART optimization be earlier considered.
format Online
Article
Text
id pubmed-9066819
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90668192022-05-04 Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China Liu, Pengtao You, Yinghui Liao, Lingjie Feng, Yi Shao, Yiming Xing, Hui Lan, Guanghua Li, Jianjun Ruan, Yuhua Li, Dan BMC Infect Dis Research BACKGROUND: Maintaining plasma HIV RNA suppression below the limit of quantification is the goal of antiretroviral therapy (ART). When viral loads (VL) remain in low-level viremia (LLV), or between 201 and 999 copies/mL, the clinical consequences are still not clear. We investigated the occurrence of LLV with drug resistance and its effect on CD4 cell counts in a large Chinese cohort. METHODS: We analysed data of 6,530 ART-experienced patients (42.1 ± 10.9 years; 37.3% female) from the China’s national HIV drug resistance (HIVDR) surveillance database. Participants were followed up for 32.9 (IQR 16.7–50.5) months. LLV was defined as the occurrence of at least one viral load (VL) measurement of 50–200 copies/mL during ART. Outcomes were drug resistance associated mutations (DRAM) and CD4 cell counts levels. RESULTS: Among 6530 patients, 58.0% patients achieved VL less than 50 copies/mL, 27.8% with VL between 50 and 999 copies/mL (8.6% experienced LLV), and 14.2% had a VL ≥ 1000 copies/mL. Of 1818 patients with VL 50–999 copies/mL, 182 (10.0%) experienced HIVDR, the most common DRAM were M184I/V 28.6%, K103N 19.2%, and V181C/I/V 10.4% (multidrug resistance: 27.5%), and patients with HIVDR had a higher risk of CD4 cell counts < 200 cells/μL (AOR 3.8, 95% CI 2.6–5.5, p < 0.01) comparing with those without HIVDR. Of 925 patients with VL ≥ 1000 copies/mL, 495 (53.5%) acquired HIVDR, the most common DRAM were K103N 43.8%, M184I/V 43.2%, M41L 19.0%, D67N/G 16.4%, V181C/I/V 14.5%, G190A/S 13.9% and K101E 13.7% (multidrug resistance: 75.8%), and patients with HIVDR had a higher risk of CD4 cell counts < 200 cells/μL (AOR 5.8, 95% CI 4.6–7.4, p < 0.01) comparing with those without HIVDR. CONCLUSION: Persistent with VL 50–999 copies/mL on ART is associated with emerging DRAM for all drug classes, and patients in this setting were at increased risk of CD4 cell counts < 200 cells/μL, which suggest resistance monitoring and ART optimization be earlier considered. BioMed Central 2022-05-04 /pmc/articles/PMC9066819/ /pubmed/35509014 http://dx.doi.org/10.1186/s12879-022-07417-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Pengtao
You, Yinghui
Liao, Lingjie
Feng, Yi
Shao, Yiming
Xing, Hui
Lan, Guanghua
Li, Jianjun
Ruan, Yuhua
Li, Dan
Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China
title Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China
title_full Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China
title_fullStr Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China
title_full_unstemmed Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China
title_short Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China
title_sort impact of low-level viremia with drug resistance on cd4 cell counts among people living with hiv on antiretroviral treatment in china
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066819/
https://www.ncbi.nlm.nih.gov/pubmed/35509014
http://dx.doi.org/10.1186/s12879-022-07417-z
work_keys_str_mv AT liupengtao impactoflowlevelviremiawithdrugresistanceoncd4cellcountsamongpeoplelivingwithhivonantiretroviraltreatmentinchina
AT youyinghui impactoflowlevelviremiawithdrugresistanceoncd4cellcountsamongpeoplelivingwithhivonantiretroviraltreatmentinchina
AT liaolingjie impactoflowlevelviremiawithdrugresistanceoncd4cellcountsamongpeoplelivingwithhivonantiretroviraltreatmentinchina
AT fengyi impactoflowlevelviremiawithdrugresistanceoncd4cellcountsamongpeoplelivingwithhivonantiretroviraltreatmentinchina
AT shaoyiming impactoflowlevelviremiawithdrugresistanceoncd4cellcountsamongpeoplelivingwithhivonantiretroviraltreatmentinchina
AT xinghui impactoflowlevelviremiawithdrugresistanceoncd4cellcountsamongpeoplelivingwithhivonantiretroviraltreatmentinchina
AT languanghua impactoflowlevelviremiawithdrugresistanceoncd4cellcountsamongpeoplelivingwithhivonantiretroviraltreatmentinchina
AT lijianjun impactoflowlevelviremiawithdrugresistanceoncd4cellcountsamongpeoplelivingwithhivonantiretroviraltreatmentinchina
AT ruanyuhua impactoflowlevelviremiawithdrugresistanceoncd4cellcountsamongpeoplelivingwithhivonantiretroviraltreatmentinchina
AT lidan impactoflowlevelviremiawithdrugresistanceoncd4cellcountsamongpeoplelivingwithhivonantiretroviraltreatmentinchina